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Abstract Thrombotic events are common and potentially
fatal complications in patients receiving hematopoietic stem
cell transplantation (HSCT). Early diagnosis is crucial but
remains controversial. In this study, we investigated the early
alterations of hemostatic parameters in allogeneic HSCT
recipients and determined their potential diagnostic values in
transplantation-related thrombotic complications and other
post-HSCTevents. Results from 107 patients with allogeneic
HSCTshowed higher levels of plasma plasminogen activator
inhibitor-1 (P AI-1), fibrinogen, and tissue-plasminogen acti-
vator (t-P A) and a lower level of plasma protein C after
transplantation. No change was found for prothrombin time,
antithrombin III, D-dimer, and activated partial thromboplas-
tin time following HSCT. Transplantation-related complica-
tions (TRCs) in HSCT patients were defined as thrombotic
(n=8), acute graft-versus-host disease (aGVHD, n=45), and
infectious (n=38). All patients with TRCs, especially the
patients with thrombotic complications, presented significant
increases in the mean and maximum levels of PAI-1 during
the observation period. Similarly, a high maximum t-PA level
was found in the thrombotic group. In contrast, apparent
lower levels of mean and minimum protein C were observed
in the TRC patients, especially in the aGVHD group.
Therefore, the hemostatic imbalance in the early phase of
HSCT, reflecting prothrombotic state and endothelial injury
due to the conditioning therapy or TRCs, might be useful in
the differential diagnosis of the thrombotic complication
from other TRCs.
Keywords Thrombotic complication.Transplantation-
related complications (TRCs).Plasminogen activator
inhibitor-1 (PAI-1).Protein C (PC).Hematopoietic stem
cell transplantation (HSCT)
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is
an effective strategy for a variety of hematological disorders
[1–3]. Improvements in human leukocyte antigen typing and
increased experience in managing transplantation-related
complications (TRCs) have resulted in decreased morbidity
and mortality following HSCT during the last decade [4–6].
Nonetheless, thrombotic events are recognized as the
common and potentially fatal complications in HSCT
recipients, such as hepatic veno-occlusive disease (VOD),
transplantation-related thrombotic microangiopathy (TA-
TMA), catheter-associated thrombosis, and deep vein throm-
bosis (DVT). It is generally assumed that endothelium
damage and coagulation disturbance induced by pre-
transplant conditioning regimens or some other factors may
contribute to the development of thrombotic events [7–9].
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their clinical manifestations are non-specific and may be
similar to a number of other TRCs, such as acute graft-
versus-host disease (aGVHD) and infection. Therefore,
prompt finding of thrombotic events is essential for the
differential diagnosis and effective early therapy.
Many hemostatic abnormalities have been reported in
various thrombotic events following allogeneic HSCT, in-
cluding fibrinolytic and coagulation parameters [10]. In
particular, elevated levels of plasma plasminogen activator
inhibitor (P AI-1) antigen have been observed in patients with
VOD or TA-TMA [11–15] and serve as one crucial non-
invasive tool for the diagnosis of VOD [11]. The changes of
other hemostatic parameters, including plasma protein C
(PC), tissue-plasminogen activator (t-P A), antithrombin III
(A TIII), and D-dimer (D-Di), have also been described in
TRCs [12, 14, 16, 17]. However, the early discrimination of
thrombotic event from other complications has not been
successfully defined. We conducted a prospective survey to
investigate the correlation of hemostatic parameters with
TRCs at predetermined time points to evaluate their values in
the differential diagnosis of TRCs.
Patients and methods
Patients and transplant procedure
One hundred and seven patients (67 males and 40 females)
receiving allogeneic HSCT from May 2006 to August 2009
were enrolled in this study, with a median age of 33 years
(range, 10–59), including eight patients under 18 years old (8/
107, 7.5%). Patients were admitted for a variety of hemato-
logic disorders at various disease stages. Human leukocyte
antigen (HLA) typing of the recipients and donors was
performed by high-resolution DNA typing using polymerase
chain reaction sequence-specific oligonucleotides for both
HLA class I (HLA-A, HLA-B, HLA-C) and class II (HLA-
DRB1, HLA-DQB1) loci. Matching was defined as 10/10
fully matched. The patients and transplant characteristics
were summarized in Table 1. All patients or their legal
representatives signed their informed consents, and the local
ethics committee approved this study.
All patients were nursed in laminar airflow rooms and
received a standard regimen for the prevention of infectious
complications (non-absorbable antibiotics for gut decon-
tamination, ganciclovir and cotrimazole for virus and Pneu-
mocystis infections, fluconazole for fungal prophylaxis,
and hyperhydration and mesna for the prevention of
cyclophosphamide-induced hemorrhagic cystitis). All cellu-
lar blood products were leukocyte-depleted and irradiated
prior to transfusion. All allogeneic patients received prophy-
lactic therapy with cyclosporine and methotrexate for
GVHD, with a continuous i.v. infusion of cyclosporine
(3mg/kg)over24hstartingonday −2andi.v.administrations
of methotrexate with the dose of 15 mg/m
2 on day 1 and
10 mg/m
2 on days 3, 6, and 11 (total dose, 45 mg/m
2).
Unrelated and mismatched patients also received antithymo-
cyte globulin (A TG) and mycophenolate mofetil (MMF) for
GVHD prophylaxis, with A TG (Rabbit Anti-human Thymo-
cyte Globulin, IMTIX-SANGSTA T, France) (2.5 mg/kg once
daily i.v.) administered from days −5t o−3 and MMF
(15 mg/kg twice daily p.o.) starting on day −10. For
prevention of thrombotic complications, a continuous i.v.
infusion of low-dose heparin (100 U/kg) over 24 h and a
three-time daily i.v. prostaglandin E1 (10 μg) were admin-
istered from days −10 to 28. Total parenteral nutrition was
given if indicated.
Classification of TRCs
Patients were evaluated once a week for TRC, and the
occurrence of aGVHD, VOD, TMA, DVT, and infection
was described in Table 2. aGVHD was assessed and graded
by clinical and biological criteria according to Klingebiel
and Schlegel [18].
Table 1 The characteristics of patients
Characteristics Patients (%)
Total 107
Sex
Male 67 (62.6)
Female 40 (37.7)
Median age (years, range) 33 (10–59)
Underlying disease
Chronic myeloid leukemia 33 (30.7)
Acute myeloid leukemia 39 (36.4)
Acute lymphoblastic leukemia 21 (19.6)
Lymphoma 8 (7.5)
Others 6 (5.3)
Type of transplant
Matched unrelated donor 24 (22.8)
Matched related donor 75 (70.1)
Mismatched related donor 8 (7.0)
Conditioning regimen
Bu-Cy 75 (70.1)
TBI-Cy 23 (21.5)
Flu-Cy-A TG 6 (5.3)
Others 3 (2.6)
Stem cells infused CD34
+ (10
6/kg, range) 3.82 (0.03–21.63)
ANC engraftment (days, range) 12 (10–20)
Bu busulfan, Cy cyclophosphamide, TBI total body irradiation, Flu
fludarabine, ANC engraftment day on which the absolute neutrophil
count was >0.5×10
9/l
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[19], as having two of the following before day 30: (1)
hyperbilirubinemia (bilirubin ≥34.2 μmol/l), (2) painful
hepatomegaly, and (3) unexplained weight gain (>2% from
the baseline), and no other explanation could be present for
these signs and symptoms. The diagnosis was also confirmed
by Doppler ultrasound or liver biopsy in all cases.
TMA was defined as the fulfilment of the following
definition proposed by the Blood and Marrow Transplant
Clinical Trials Network [20]: (1) RBC fragmentation with
two schistocytes per high-power field on peripheral smear,
(2) concurrent increased serum LDH above institutional
baseline, (3) concurrent renal and/or neurologic dysfunction
without other explanations, and (4) negative direct and
indirect coombs' test results. Diagnosis of DVT was based
upon a positive result of ultrasound or venography.
Infectious complications were defined by clinical and
laboratory parameters [21]: (1) body temperature ≥38.5°C
on a single occasion or ≥38°C on two separate occasions
among 6-h intervals; (2) exclusion of other fever origins,
effective antibiotic therapy; (3) positive microorganisms in
blood, sputum, or urine cultures.
Assays of hemostatic parameters
V enous blood was drawn weekly in the morning from
2 weeks (week −2) prior to stem cell infusion (week 0) until
4 weeks after transplantation (week +4) and was anti-
coagulated with 1:9 volumes of 3.8% sodium citrate.
Plasma samples were obtained by centrifugation within
1 h (3,000×g for 15 min) for complete platelet removal.
Aliquots were frozen and stored at −80°C until assayed.
Plasma levels of various hemostatic parameters were
monitored by standard techniques. PAI-1, t-PA, and PC
antigens were determined by enzyme-linked immunosorbent
assay (Shanghai Sun Biotech, Shanghai, China) following the
manufacturer's instructions (normal ranges, 5–45 ng/ml for
PAI-1, 1.0–12 ng/ml for t-PA, 3.0–5.2 μg/ml for PC).
Activated partial thromboplastin time (APTT; normal range,
28–40 s), prothrombin time (PT; normal range, 11–14.5 s),
fibrinogen (Fg; normal range, 2–5 μg/ml), A TIII (normal
range, 80–120%), and D-Di (normal range, 0.01–0.5 μg/ml)
were performed on the hemagglutinin equipment (Diagnos-
tica Stago, Asnieres, France).
Statistical analysis
Statistical analysis was performed using SPSS 11.5 soft-
ware. The results were expressed as mean ± standard
deviation. Categorical variables were analyzed using the
chi-square test and by Mann–Whitney U for group differ-
ences. Continuous variables were compared with Student's t
test. All tests used an α level of 0.05, and P<0.05 was
considered statistically significant.
Results
Characteristics and complications of patients receiving
HSCT
The characteristics of patients were shown in Table 1.O f1 0 7
patients, 24 transplants were from matched unrelated
donors, 75 from matched related donors, and 8 from
mismatched related donors. The disease status at trans-
plant was not related to the alteration of hemostatic
parameters. The pre-transplant conditioning regimen
i n c l u d e dB u - C yi n7 5( 7 0 . 1 % )c a s e s ,T B I - C yi n2 3
(21.5%), Flu-Cy-A TG in 6 (5.3%), and others in the
remaining 3 (2.6%) cases. Median number of CD34
+ cell
infusion was 3.82×10
6/kg (range, 0.03–21.63). Median
absolute neutrophil count (ANC) engraftment (>0.5×10
9/l)
was 12 days (range, 10–20) with no significant difference
among different groups.
Complications Patients (%)
Total TRCs First-onset TRCs Single TRCs
Acute GVHD 45 (42.1) 38 (35.5) 22 (20.6)
Grade 1 23 (21.5) 21 (19.6) 14 (13.1)
≥Grade 2 22 (20.6) 17 (15.9) 8 (7.5)
Thrombotic complications 8 (7.5) 7 (6.5) 3 (2.8)
VOD 6 (5.6) 5 (4.7) 2 (1.9)
TMA 1 (0.9) 1 (0.9) 0 (0)
DVT 1 (0.9) 1 (0.9) 1 (0.9)
Infection 38 (35.5) 28 (26.2) 20(18.7)
≥2 complications 28 (26.2)
No complication 34 (31.8)
Table 2 Transplantation-related
complications
Ann Hematol (2011) 90:1201–1208 1203Three groupsofTRCs weredefinedbytheir corresponding
criteria as shown in Table 2. Ninety-one complications
occurred in all patients observed, of which 45 met the
aGVHD criteria (22 with grades 2–4), 8 were classified as
thrombotic complications (6 VOD, 1 TA-TMA, 1 DVT), and
38 were diagnosed as infectious complications. Twenty-eight
patients were found to have at least two types of complica-
tions, and 34 patients had no complications during the
observation period. Based on the first-onset complications
following HSCT, 38 patients presented with aGVHD, 28
with infection, and 7 with thrombotic complication. When
grouped with single complication, 22 patients were compli-
cated with aGVHD, 3 with thrombosis, and 28 with
infection.
Changes of hemostatic parameters during HSCT
We measured plasma levels of hemostatic parameters in all the
patients who underwent HSCT. Results were given as mean±1
standard deviation (SD). Week 0 is defined as the week
immediately after stem cell transfusion. As shown in Table 3,
although plasma levels of APTT, A TIII, PT, and D-Di were
normal, plasma PAI-1, PC, t-PA, and Fg antigen levels were
changed in patients receiving HSCT. During conditioning
treatment (week −1), a significant increase in PAI-1 and an
apparent decrease in PC were observed followed by
remarkable diminutions of PAI-1 and t-PA levels and an
elevation of PC level immediately after stem cell transfusion
(week 0). After grafting, levels of PAI-1 and t-PA increased,
while PC decreased in the first week of transplantation and
then increased throughout the observation period. In addition,
fibrinogen showed a significant increase after transplantation.
Alteration of plasma levels of PAI-1 and PC in patients
with TRCs during HSCT
We next analyzed the correlations of plasma levels of PAI-1
and PC with TRCs in the course of HSCT. Before
conditioning therapy, patients with or without complications
did not show any significant difference in the mean plasma
PAI-1 antigen levels. Their PAI-1 levels increased during
the conditioning period (P<0.05), decreased immediately
after stem cell transfusion, and then increased after
engraftment (P<0.05). However, patients with complica-
tions presented with a tendency of increased PAI-1
compared with those without complication during the
conditioning period and the first 2 weeks after transplanta-
tion (P<0.05). Among them, patients with thrombotic
complications showed a more significant increase in plasma
PAI-1 throughout the observation period (Fig. 1a). Similar
to plasma PAI-1, protein C antigen levels in patients with or
without complications were normal before conditioning
(week −2), but dropped during conditioning phase
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1204 Ann Hematol (2011) 90:1201–1208(P<0.05) followed by a small increase immediately after
transplantation (week 0). After engraftment, plasma PC of
all patients showed the lowest levels in the first week of
transplantation and then returned to normal range. Patients
with complications had lower plasma PC levels compared
with those without complication after transplantation
(P<0.05), of which patients with aGVHD showed the
lowest PC level (Fig. 1b).
Maximum levels of plasma PAI-1 and t-PA and minimum
level of PC in patients receiving HSCT in the early phase
of TRCs
During transplantation, patients were grouped based on the
first-onset complications following allogeneic HSCT. Of
107 patients, 38 presented with aGVHD, 28 with infection,
7 with thrombotic complication, and 34 without complica-
tion. When plasma levels of PAI-1, PC, and t-PA were
analyzed using peak values, patients with complications
showed higher maximum plasma PAI-1 levels than those
without complications during the observation weeks (P<
0.05). Maximum values of PAI-1 in all patients with
thrombotic complications were above the normal range of
plasma PAI-1 (5–45 ng/ml) (7/7, 100%), while 16 cases in
the aGVHD group (16/38, 42.1%) and 15 cases in the
infection group (14/28, 50.0%) showed abnormal maxi-
mum levels of PAI-1 antigen. Moreover, the peak PAI-1
antigen levels were even higher in seven patients with
thrombotic complications than those in patients with other
TRCs (thrombosis, 62.77±7.46 ng/ml; aGVHD, 44.12±
8.16 ng/ml, P<0.05; infection, 47.95±9.19 ng/ml, P<0.05)
(Fig. 2a). On the contrary, all the patients with three
different complications presented with significantly low
minimum level of protein C in comparison with those
without complications (P<0.05). The minimum PC levels
were apparently lower in the GVHD patients than those in
patients with other TRCs (aGVHD, 1.87±0.52 μg/ml;
thrombosis, 2.38±0.55 μg/ml; infection, 2.67±0.45 μg/ml.
P<0.05) (Fig. 2b). In addition, the maximum t-PA antigen
levels in seven patients with thrombotic complications were
significantly higher than those in patients with other
complications in the course of the investigation (thrombosis,
33.33±6.11 ng/ml; aGVHD, 18.92±6.33 ng/ml; infection,
13.82±5.75 ng/ml. P<0.05). There was no statistical
Fig. 1 Plasma levels of PAI-1
and PC antigens in
transplantation-related compli-
cations during allogeneic HSCT.
Week 0 is defined as the week
immediately after stem cell
transfusion; a showed that PAI-1
levels (mean ± SD) were ele-
vated significantly in patients
following pre-conditioning and
transplantation. All the patients
with three different complica-
tions presented with a tendency
of increased PAI-1 compared
with those who had no compli-
cation (*P<0.05) and showed a
remarkable elevation in the
patients with thrombotic com-
plications; b showed that visible
decreases of PC levels (mean ±
SD) were found following pre-
conditioning and transplanta-
tion. All the patients with three
different complications pre-
sented with lower level of PC
compared with those who had
no complication (*P<0.05) and
showed a remarkable diminution
in the patients with aGVHD.
△P<0.05: compared with the
initial value before conditioning,
week −2. #P<0.05: compared
with the value after stem cell
transfusion, week 0
Ann Hematol (2011) 90:1201–1208 1205difference in the peak t-PA antigen levels among the patients
with aGVHD and infection, and those without complications
(Fig. 2c).
Discussion
Thrombotic events closely related to endothelium injuries and
coagulation disturbance are severe and life-threatening com-
plications in allogeneic HSCT recipients. The incidences of
the most common two types, VOD (frequency, 1–54%) [8]
and TA-TMA (frequency, 0.5–63.6%) [22], vary greatly
according to different criteria. Our observation showed that
eight patients developed thrombotic complications in 107
patients following allogeneic HSCT (7.5%), including six
VOD, one TA-TMA, and one DVT. The incidences of VOD
(5.6%) and TA-TMA (0.9%) were in the lower range of other
reports [8, 22], probably due to the difference in race or
diagnostic criteria for TA-TMA.
The low specificity and late onset of diagnostic clinical
signs of thrombotic complications hinder their early
recognition and differential diagnosis from other TRCs.
Since the early and rational treatments can improve
outcomes for patients affected by these complications of
HSCT, early diagnosis of thrombotic events is essential [23,
24]. We have determined some predictive laboratory
markers for the differential diagnosis of early TRCs and
performed a systemic survey of hemostatic parameters in
allogeneic HSCT recipients. The most notable findings
were the dramatic alterations of plasma PAI-1 and protein C
levels in the patients with TRCs.
PAI-1, a physiologic antagonist of t-PA, mainly synthe-
sized and released by endothelial cells [25], is the major
inhibitor of the fibrinolytic enzyme cascade [26]. It has
been proposed to be an early marker of VOD diagnosis
both in pediatric and adult HSCT patients [11, 12]. PAI-1
inhibitor could prevent hepatic venous injury in murine
models, and PAI-1-deficient mice were protected largely
Fig. 2 Maximum plasma PAI-1,
t-PA, and minimum PC in
patients with TRCs following
HSCT. a Gray background
shows the normal range of
plasma PAI-1 antigen levels
(5–45 ng/ml), marks indicate the
maximum PAI-1 antigen levels,
and bars show the 95% CI. b
Gray background shows the
normal range of plasma PC
antigen levels (3.0–5.2 μg/ml).
Marks indicate the minimum
plasma PC antigen level, and
bars show the 95% CI. c Gray
background shows the normal
range of plasma t-PA antigen
levels (1.0–12 ng/ml). Marks
indicate the maximum t-PA
antigen levels, and bars show
the 95% CL. (△P<0.05:
compared to the thrombotic
group, ▼P<0.05: compared to
the GVHD group, #P<0.05:
compared to the infectious
group)
1206 Ann Hematol (2011) 90:1201–1208from VOD [27]. Some investigators also reported an
elevated level of PAI-1 or t-PA/PAI in TA-TMA [14, 15].
We found a significant elevation of mean plasma PAI-1
antigen in the patients with complications before and after
2 weeks of stem cell transfusion, with which a most
significant increase in plasma PAI-1 occurred in patients
with thrombotic complication throughout the observation
period. This result was similar to the findings of others [11–
15], demonstrating an endothelial injury by conditioning,
transplantation complications, and the activation of the
fibrinolytic system. Most importantly, the evidence that the
peak plasma PAI-1 antigen levels in our studies presented in
patients with complications suggested that the maximum
PAI-1 plasma level could be a useful predictive marker for
the early diagnosis of TRCs in HSCT patients. Moreover,
the highest plasma PAI-1 level in patients with thrombotic
complication could be used to discriminate thrombotic
events from other TRCs in allogeneic HSCT patients [11].
In addition, our data also showed a significant higher level
of maximum plasma t-PA antigen only in the thrombotic
group, implying that peak t-PA antigen could be used in
combination with PAI-1 to predict the early diagnosis of
thrombotic complications.
Protein C plays an important role in preventing blood
clot formation in vivo. Upon activation, PC functions as an
anticoagulant by inactivating factors V a and VIIIa [28].
Several reports analyzed PC and another natural anticoag-
ulant A TIII to define their values in the diagnosis of TRCs
[29]. However, the results were controversial. Some studies
suggested that the decrease of plasma PC or A TIII reflects
the development of VOD [29, 30], portal vein thrombosis
[31], or early occurrence of TRCs [18], while others could
not verify their roles in the differential diagnosis of TRCs
[14, 16]. We observed the diminution of mean and
minimum plasma PC levels in the patients with TRC after
HSCT, indicating the correlation of plasma PC level with
the development of TRCs. Furthermore, the lowest levels of
mean and minimum PC were observed in the patients with
aGVHD, suggesting the early post-BMT reduction of PC
might predict the occurrence of aGVHD.
Although other studies showed many subclinical clotting
and fibrinolytic profile changes during the period following
conditioning chemotherapy and the period after transplanta-
tion [32], we did not find any significant change in the
parameters of APTT, A T, PT, and D-Di, probably owing to the
modified treatment or the heterogeneity of Chinese patients.
We also grouped patients based on single or multiple
complications. We found that the peak PAI-1 antigen levels
were higher in patients with only thrombotic complication
than those with other single TRCs. The minimum PC levels
were apparently lower in the aGVHD patients than those in
patients with other single TRCs. The maximum t-PA
antigen levels in patients with only thrombotic complication
were significantly higher than those in patients with other
single complications. These results were consistent with
those obtained when patients were grouped by the first
onset of complications.
In summary, alteration of hemostatic parameters during
the early phase of HSCT reflects endothelial injury or a
hypercoagulable state in patients undergoing allogeneic
HSCT, which contributes to the development of TRCs. The
increase in plasma PAI-1 levels, particularly in combination
with increased t-PA level, can be used as a marker for the
early discrimination of thrombotic complication from other
TRCs, while the reduction of PC might be considered as a
good parameter to the early diagnosis of aGVHD. These
findings would be useful in improving the early discrimi-
nation and correct treatment of TRCs.
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